441 related articles for article (PubMed ID: 28946567)
1. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
[TBL] [Abstract][Full Text] [Related]
2. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.
Rafii MS; Wishnek H; Brewer JB; Donohue MC; Ness S; Mobley WC; Aisen PS; Rissman RA
Front Behav Neurosci; 2015; 9():239. PubMed ID: 26441570
[TBL] [Abstract][Full Text] [Related]
3. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
[TBL] [Abstract][Full Text] [Related]
5. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
6. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.
Rafii MS
Dev Neurobiol; 2019 Jul; 79(7):711-715. PubMed ID: 30536948
[TBL] [Abstract][Full Text] [Related]
7. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Donohue MC; Matthews DC; Muranevici G; Ness S; O'Bryant SE; Rissman RA
J Alzheimers Dis; 2019; 70(1):131-138. PubMed ID: 31156181
[TBL] [Abstract][Full Text] [Related]
8. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.
Neale N; Padilla C; Fonseca LM; Holland T; Zaman S
Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
Wisch JK; McKay NS; Boerwinkle AH; Kennedy J; Flores S; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant SE; Price JC; Laymon CM; Krinsky-McHale SJ; Lai F; Rosas HD; Hartley SL; Zaman S; Lott IT; Tudorascu D; Zammit M; Brickman AM; Lee JH; Bird TD; Cohen A; Chrem P; Daniels A; Chhatwal JP; Cruchaga C; Ibanez L; Jucker M; Karch CM; Day GS; Lee JH; Levin J; Llibre-Guerra J; Li Y; Lopera F; Roh JH; Ringman JM; Supnet-Bell C; van Dyck CH; Xiong C; Wang G; Morris JC; McDade E; Bateman RJ; Benzinger TLS; Gordon BA; Ances BM; ;
Lancet Neurol; 2024 May; 23(5):500-510. PubMed ID: 38631766
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
11. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
Botha H; Mantyh WG; Murray ME; Knopman DS; Przybelski SA; Wiste HJ; Graff-Radford J; Josephs KA; Schwarz CG; Kremers WK; Boeve BF; Petersen RC; Machulda MM; Parisi JE; Dickson DW; Lowe V; Jack CR; Jones DT
Brain; 2018 Apr; 141(4):1201-1217. PubMed ID: 29538658
[TBL] [Abstract][Full Text] [Related]
13. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
[TBL] [Abstract][Full Text] [Related]
14. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
[TBL] [Abstract][Full Text] [Related]
15. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
16. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.
Benvenutto A; Giusiano B; Koric L; Gueriot C; Didic M; Felician O; Guye M; Guedj E; Ceccaldi M
J Alzheimers Dis; 2018; 65(4):1147-1157. PubMed ID: 30124446
[TBL] [Abstract][Full Text] [Related]
17. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.
Lee SH; Cho H; Choi JY; Lee JH; Ryu YH; Lee MS; Lyoo CH
Mov Disord; 2018 Feb; 33(2):262-272. PubMed ID: 29168583
[TBL] [Abstract][Full Text] [Related]
18. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
[TBL] [Abstract][Full Text] [Related]
19. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
[TBL] [Abstract][Full Text] [Related]
20. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images.
Malotaux V; Colmant L; Quenon L; Huyghe L; Gérard T; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
J Alzheimers Dis; 2024; 97(1):421-433. PubMed ID: 38108350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
